Generic Drug Market in Canada

Published by: RNCOS

Published: Feb. 1, 2008 - 85 Pages

Table of Contents

1. Analyst View

2. Canadian Pharmaceutical Market

2.1 Market Size & Growth

2.1.1 Prescriptions

2.1.2 Sales

2.2 Key Therapy Areas

2.3 Branded & Generic Drugs

2.4 Sources of Drug Payment

2.5 Key Players

2.5.1 Prescriptions

2.5.2 Sales

2.6 Top Selling Drugs

2.6.1 Prescriptions

2.6.2 Sales

3. Canadian Generic Market

3.1 Market Size & Growth

3.1.1 Prescriptions

3.1.2 Sales

3.2 Key Players

3.2.1 Prescriptions

3.2.2 Sales

3.3 Market Segmentation

3.3.1 Distribution Channels

3.3.1.1 Retail Pharmacies

3.3.1.1.1 Sales

3.3.1.1.2 Key Players

3.3.1.2 Hospital Pharmacies

3.3.1.2.1 Sales

3.3.1.2.2 Key Players

3.3.2 Authorized & Independent Generics

3.3.3 Province/Territory

3.3.3.1 Drug Consumption

3.3.3.2 Prescriptions

3.3.3.3 Sales

3.4 Generic Approval Process

3.4.1 Abbreviated New Drug Submission

3.4.2 Notice of Allegation

4. Industry Analysis

4.1 Market Drivers

4.1.1 Huge Cost Savings

4.1.2 Favorable Political Environment

4.1.3 Patent Expirations

4.1.4 Ageing Population

4.1.5 High Returns for Pharmacists

4.2 Opportunity Areas

4.2.1 Cardiovascular Drugs

4.2.2 Cancer Drugs

4.2.3 Psychotherapeutics

4.2.4 Antidiabetics

4.2.5 Drug Packaging & Delivery Market

4.3 Restraining Factors

4.3.1 Extension of Data Exclusivity

4.3.2 Export Restrictions

4.3.3 Evergreening of Drug Patents

4.3.4 Authorized Generics

4.4 Future Outlook (2008-2012)

4.4.1 Driving & Restraining Forces

4.4.2 Future Scenario (2008-2012)

5. Supporting Databases

5.1 Macroeconomic Indicators

5.2 Population Profile

5.3 Age Profile

5.4 Healthcare Spending & Infrastructure

6. Key Player Profiles

6.1 Apotex Inc

6.2 Mylan Laboratories Inc

6.3 Teva Pharmaceutical Industries Limited

6.4 Ratiopharm GmbH

6.5 Sandoz Inc

6.6 Pharmascience Inc.

List of Figures:

Figure 2-1: Canada - Prescriptions Dispensed* in Pharmaceutical Market (in ‘000), 2001-2007E

Figure 2-2: Canada - Pharmaceutical Sales* (in Billion CA$), 2001-2007E

Figure 2-3: Canada - Pharmaceutical Purchases* by Retail & Hospital Pharmacies (in Billion CA$), 2001-2007E

Figure 2-4: Canada - Deaths by Various Causes (%), 2005-2007E

Figure 2-5: Canada - Share of Generic & Branded Drug by Prescription* (%), 2007E

Figure 2-6: Canada - Share of Generic & Branded Drug by Sales (%), 2007E

Figure 2-7: Canada - Drug Financing by Source (%), 2006

Figure 3-1: Canada - Prescriptions Dispensed* in Branded Drug Market (in ‘000), 2001-2007E

Figure 3-2: Canada - Prescriptions Dispensed* in Generic Drug Market (in ‘000), 2001-2007E

Figure 3-3: Canada - Share of Generic & Branded Drug by Prescription (%), 2001-2007E

Figure 3-4: Canada - Generic Drug Sales (in Billion CA$), 2001-2007E

Figure 3-5: Canada - Branded Drug Sales (in Billion CA$), 2001-2007E

Figure 3-6: Canada - Share of Generic & Branded Drug by Sales (%), 2001-2007E

Figure 3-7: Canada - Relation between Brand Sales & Number of Generic Entrants

Figure 3-8: Canada - Branded Drug Sales through Retail Pharmacies (in Billion CA$), 2004-2007E

Figure 3-9: Canada - Generic Drug Sales through Retail Pharmacies (in Billion CA$), 2004-2007E

Figure 3-10: Canada - Share of Generic & Branded Drug Sales through Retail Pharmacies (%), 2004-2007E

Figure 3-11: Canada - Branded Drug Sales through Hospital Pharmacies (in Billion CA$), 2004-2007E

Figure 3-12: Canada - Generic Drug Sales through Hospital Pharmacies (in Billion CA$), 2004-2007E

Figure 3-13: Canada - Share of Generic & Branded Drug Sales through Hospital Pharmacies (%), 2004-2007E

Figure 3-14: Canada - Share of Independent Generic & Authorized Generic Prescriptions (%), 2001-2007E

Figure 4-1: Canada - Average Cost of Branded & Generic Drug (in CA$), 2001-2006

Figure 4-2: Canada - Population above 65 Years of Age (in Million), 2001-2007E

Figure 4-3: Canada - Relative Per Capita Spending on Drug by Age Group

Figure 4-4: Canada - Cardiovascular Drug Market* (in Billion CA$), 2005-2007E & 2012F

Figure 4-5: Canada - Antineoplastics Market* (in Million CA$), 2005**, 2006** & 2012F**

Figure 4-6: Canada - Psychotherapeutics Market* (in Billion CA$), 2005-2007E & 2012F

Figure 4-7: Canada - Number of Diabetes Patients in Age Group 20-79 Years (in ‘000), 2003, 2007E & 2025F

Figure 4-8: Canada - Diabetes Market* (in Million CA$), 2005-2007E & 2012F

Figure 4-9: Canada - Forecast for Population above 65 Years of Age (in Million), 2008-2011

Figure 4-10: Canada - Forecast for Deaths by Various Causes (%), 2008-2012 & 2030

Figure 4-11: Canada - Forecast for Pharmaceutical Sales (in Billion CA$), 2008-2012

Figure 4-12: Canada - Forecast for Generic Drug Sales (in Billion CA$), 2008-2012

Figure 4-13: Canada - Forecast for Branded Drug Sales (in Billion CA$), 2008-2012

Figure 4-14: Canada - Forecast for Share of Branded & Generic Drugs by Prescription (%), 2008-2012

Figure 4-15: Canada - Forecast for Branded & Generic Drugs by Sales (%), 2008-2012

Figure 4-16: Canada - Forecast for Contribution of Branded & Generic Drug Sales in Growth of Pharmaceutical Market (%), 2007 to 2012

Figure 5-1: Canada - Nominal GDP (in Million US$), 2001-2007E

Figure 5-2: Canada - Consumer Price Index (%), 2001-2007E

Figure 5-3: Canada - Forecast for Consumer Price Index (%), 2008-2011

Figure 5-4: Canada - Currency Exchange Rates (From CA$ to US$), 2001-2007

Figure 5-5: Canada - Population (in Million), 2001-2007E

Figure 5-6: Canada - Forecast for Population (in Million), 2008-2011

Figure 5-7: Canada - Life Expectancy (in Years), 2001-2007E

Figure 5-8: Canada - Forecast for Life Expectancy (in Years), 2008-2011

Figure 5-9: Canada - Population Breakup by Age Group (%), 2002-2007E

Figure 5-10: Canada - Forecast for Population Breakup by Age Group (%), 2008-2011

Figure 5-11: Canada - Per Head Healthcare Spending (in US$), 2001-2007E

Figure 5-12: Canada - Forecast for Per Head Healthcare Spending (in US$), 2008-2011

Figure 5-13: Canada - Number of Doctors (per ‘000 Population), 2002-2007E

Figure 5-14: Canada - Forecast for Number of Doctors (per ‘000 Population), 2008-2011

Figure 5-15: Canada - Number of Hospital Beds (per ‘000 Population), 2001-2007E

Figure 5-16: Canada - Forecast for Number of Hospital Beds (per ‘000 Population), 2008-2011

List of Tables:

Table 2-1: Canada - Top 10 Therapy Areas by Prescription* (in ‘000), 2006

Table 2-2: Canada - Top 10 Therapy Areas by Sales* (in ‘000 CA$), 2006

Table 2-3: Canada - Top Pharmaceutical Companies by Retail Prescription (in Million), 2006

Table 2-4: Canada - Ranking of Top Pharmaceutical Companies by Retail Prescription (2001-2006)

Table 2-5: Canada - Top Pharmaceutical Companies by Sales* (in Million CA$), 2006

Table 2-6: Canada - Ranking of Top Pharmaceutical Companies by Sales* (2001-2006)

Table 2-7: Canada - Top Drugs in Pharmaceutical Market by Prescription* (in Million), 2006

Table 2-8: Canada - Top Drugs in Pharmaceutical Market by Sales* (in Million CA$), 2006

Table 3-1: Canada - Top Generic Drug Companies by Retail Prescription (in Million), 2006

Table 3-2: Canada - Ranking of Top Generic Drug Companies by Retail Prescription (2002-2006)

Table 3-3: Canada - Top Generic Drug Companies by Sales* (in Million CA$), 2006

Table 3-4: Canada - Ranking of Top Generic Drug Companies by Sales* (2002-2006)

Table 3-5: Canada - Pharmaceutical Sales by Distribution Channel (%), 2002-2006

Table 3-6: Canada - Generic Drug Market by Retail & Hospital Sales (%), 2007E

Table 3-7: Canada - Number of Retail Pharmacies by Category (2001-2006)

Table 3-8: Canada - Top Therapy Areas by Retail Sales (in Million CA$), 2006

Table 3-9: Canada - Ranking of Top Generic Players by Retail Sales (2006)

Table 3-10: Canada - Top Therapy Areas by Hospital Sales (in Million CA$), 2006

Table 3-11: Canada - Ranking of Top Generic Players by Hospital Sales (2006)

Table 3-12: Canada - Per Capita Drug Spending of Public & Private Sector by Region (in CA$), 2006E

Table 3-13: Canada - Generic Drug Prescriptions by Region (%), 2001-2006

Table 3-14: Canada - Generic Drug Sales by Region (%), 2004 & 2006

Table 4-1: Canada - Returns for Pharmacists on Generic & Branded Drug (in CA$)

Table 6-1: Mylan Laboratories Inc. - Key Financials (in Million US$), 2005-2007

Table 6-2: Teva Pharmaceutical Industries Limited - Key Financials (in Million US$), 2004-2006

Table 6-3: Sandoz Inc. - Key Financials (in Million US$), 2005 & 2006

Abstract

• The penetration of generics is rapidly increasing in the Canadian pharmaceutical market, with generics expected to account for nearly 26% of the entire pharmaceutical sales by 2012.
• Apotex has been the leader of the Canadian generic market, controlling around 34% of the market in 2006.
• Nearly 5 Million people in Canada will be above 65 years by 2011, increasing the demand for drugs, specifically those for chronic diseases.
• Generics substitution is preferred by pharmacists as they give better returns than branded drugs.
• The top four generic companies presently control more then 70% of the generic market, but the market is expected to undergo more fragmentation in future.
• Projected growth of generics at a CAGR of 14% during 2007-2012 will surpass that of pharmaceutical market at a CAGR 7.6% during the same period.

• Evaluation of past, current and future market trends.
• Discussion about the size and growth of the market.
• Study of various distribution channels prevailing in the market.
• Analysis of healthcare indicators.
• Future prospects of the generic market.
• Profile discussion of key players in this market.
• Analysis of various challenges and opportunities for the market.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.